SGP
SpyGlass Pharma, Inc.
NASDAQ: SGP · HEALTHCARE · BIOTECHNOLOGY
$22.94
+3.66% today
Updated 2026-04-30
Market cap
$786.19M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.25
Dividend yield
—
52W range
$20 – $32
Volume
0.1M
SpyGlass Pharma, Inc. (SGP) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Gross margin | — | — | — |
| R&D | $9.96M | $19.98M | $29.18M |
| SG&A | $4.27M | $7.08M | $12.27M |
| Operating income | $-14.23M | $-27.06M | $-41.45M |
| Operating margin | — | — | — |
| EBITDA | — | — | — |
| EBITDA margin | — | — | — |
| EBIT | — | — | — |
| Interest expense | — | — | — |
| Income tax | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% |
| Net income | $-13.32M | $-29.16M | $-39.87M |
| Net income growth (YoY) | — | -119.0% | -36.7% |
| Profit margin | — | — | — |